Combination of a Selective HSP90α/β Inhibitor and a RAS-RAF-MEK-ERK Signaling Pathway Inhibitor Triggers Synergistic Cytotoxicity in Multiple Myeloma Cells

Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma

(2015) Francesco Spagnolo et al.   Oncotarget

Heat shock proteins in multiple myeloma

(2015) Lei Zhang et al.   Oncotarget

Widespread Genetic Heterogeneity in Multiple Myeloma: Implications for Targeted Therapy

(2014) Jens G. Lohr et al.   CANCER CELL

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers

(2014) A. N. Hata et al.   CANCER RESEARCH

Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma

(2014) J.P. Sharman et al.   Clinical Lymphoma Myeloma & Leukemia

Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients WithBRAFV600-Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor

(2014) Douglas B. Johnson et al.   JOURNAL OF CLINICAL ONCOLOGY

Anti-tumor activities of selective HSP90α/β inhibitor, TAS-116, in combination with bortezomib in multiple myeloma

(2014) R Suzuki et al.   LEUKEMIA

TAS-116, a Highly Selective Inhibitor of Heat Shock Protein 90  and  , Demonstrates Potent Antitumor Activity and Minimal Ocular Toxicity in Preclinical Models

(2014) S. Ohkubo et al.   MOLECULAR CANCER THERAPEUTICS

The clinical development of MEK inhibitors

(2014) Yujie Zhao et al.   Nature Reviews Clinical Oncology

Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma

(2014) Georgina V. Long et al.   NEW ENGLAND JOURNAL OF MEDICINE

Systematic identification of signaling pathways with potential to confer anticancer drug resistance

(2014) C. A. Martz et al.   Science Signaling

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

(2013) G. Mulligan et al.   BLOOD

Hsp90, an unlikely ally in the war on cancer

(2013) Jared J. Barrott et al.   FEBS Journal

Farnesyltransferase inhibitor tipifarnib inhibits Rheb prenylation and stabilizes Bax in acute myelogenous leukemia cells

(2013) H. Ding et al.   HAEMATOLOGICA

KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells

(2013) Yusuke Nakadate et al.   INTERNATIONAL JOURNAL OF CANCER

Inhibition of HSP90 molecular chaperones: moving into the clinic

(2013) Rocio Garcia-Carbonero et al.   LANCET ONCOLOGY

Tumor adaptation and resistance to RAF inhibitors

(2013) Piro Lito et al.   NATURE MEDICINE

MEK inhibitors as a chemotherapeutic intervention in multiple myeloma

(2013) C Chang-Yew Leow et al.   Blood Cancer Journal

Targeting the BRAF V600E Mutation in Multiple Myeloma

(2013) M. Andrulis et al.   Cancer Discovery

Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

(2013) H. Shi et al.   Cancer Discovery

Molecular Pathways: Targeting Hsp90--Who Benefits and Who Does Not

(2012) M. Scaltriti et al.   CLINICAL CANCER RESEARCH

Hsp90 Molecular Chaperone Inhibitors: Are We There Yet?

(2012) L. Neckers et al.   CLINICAL CANCER RESEARCH

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

(2012) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Targeting KRAS-Mutant Non-Small Cell Lung Cancer with the Hsp90 Inhibitor Ganetespib

(2012) J. Acquaviva et al.   MOLECULAR CANCER THERAPEUTICS

A Phase I Study of PF-04929113 (SNX-5422), an Orally Bioavailable Heat Shock Protein 90 Inhibitor, in Patients with Refractory Solid Tumor Malignancies and Lymphomas

(2011) A. Rajan et al.   CLINICAL CANCER RESEARCH

Novel therapies in MM: from the aspect of preclinical studies

(2011) Teru Hideshima et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Clinical and biological implications of MYC activation: a common difference between MGUS and newly diagnosed multiple myeloma

(2011) W-J Chng et al.   LEUKEMIA

Targeting HSP 90 Induces Apoptosis and Inhibits Critical Survival and Proliferation Pathways in Multiple Myeloma

(2011) T. Khong et al.   MOLECULAR CANCER THERAPEUTICS

Multiple Myeloma

(2011) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Kinase-Dead BRAF and Oncogenic RAS Cooperate to Drive Tumor Progression through CRAF

(2010) Sonja J. Heidorn et al.   CELL

New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells

(2010) T. Nakashima et al.   CLINICAL CANCER RESEARCH

Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway byNanoparticle Albumin-Bound–Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma

(2010) Diana Cirstea et al.   MOLECULAR CANCER THERAPEUTICS

RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF

(2010) Poulikos I. Poulikakos et al.   NATURE

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

(2010) Georgia Hatzivassiliou et al.   NATURE

Targeting the RAF–MEK–ERK pathway in cancer therapy

(2009) Clara Montagut et al.   CANCER LETTERS

Multiple myeloma

(2009) Marc S Raab et al.   LANCET

SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK

(2008) Y. Okawa et al.   BLOOD

Clinical and biological significance of RAS mutations in multiple myeloma

(2008) W J Chng et al.   LEUKEMIA